Skip to main content
main-content

Oncology Medicine Matters

Research news

22-06-2018 | Non-small cell lung cancer | ASCO 2018 | Article

Avelumab–lorlatinib shows efficacy for heavily pretreated ALK-positive NSCLC

The JAVELIN Lung 101 study suggests that the PD-L1 inhibitor avelumab plus the third-generation ALK inhibitor lorlatinib may be a feasible combination in non-small-cell lung cancer patients with heavily pretreated, advanced ALK-positive disease.

22-06-2018 | Early stage breast cancer | ASCO 2018 | News

Mixed results for denosumab for the prevention of breast cancer recurrence

Two opposing sets of phase III results regarding the effect of denosumab on the recurrence of hormone receptor-positive nonmetastatic breast cancer have been presented at the ASCO Annual Meeting 2018 in Chicago, Illinois, USA.

20-06-2018 | Non-small cell lung cancer | ASCO 2018 | News

Atezolizumab boosts survival in metastatic nonsquamous NSCLC

Adding atezolizumab to bevacizumab plus chemotherapy significantly delays disease progression and death among chemotherapy-naïve patients with metastatic nonsquamous non-small-cell lung cancer, phase III study data show.

Expert interviews

14-06-2018 | Lung cancer | ASCO 2018 | Video

Expert commentary: Lung cancer highlights, including the KEYNOTE-042 and CCGA studies

ASCO expert David Graham comments on the plenary KEYNOTE-042 trial, putting the findings in context of other recent research, and highlights the initial report from the CCGA study that could pave the way for a novel lung cancer screening approach. (5:02)

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Neoadjuvant chemoradiotherapy beneficial for resectable pancreatic cancer

Preliminary findings from the PREOPANC -1 trial suggest that neoadjuvant chemoradiotherapy may be beneficial for patients with resectable pancreatic cancer. Lead author Geertjan Van Tienhoven outlines the results and discusses the challenges of conducting this trial. (3:46)

Watch the accompanying expert commentary.

08-06-2018 | Lung cancer | ASCO 2018 | Video

Expert higlights: An update from ASCO 2018 on targeted therapies in lung cancer

Advisory Board member Ross Camidge takes us through the latest research on ALK inhibitors and other targeted therapies for lung cancer, including updated data from the ALEX trial (8:46).

08-06-2018 | Pancreatic cancer | ASCO 2018 | Video

Researcher comment: Adjuvant mFOLFIRINOX shows benefits over gemcitabine in pancreatic cancer

Presenting author Thierry Conroy provides an overview of the PRODIGE 24 trial showing adjuvant modified FOLFIRINOX outplays gemcitabine in patients with operable pancreatic cancer (3:58).

Read the related news story

Watch the accompanying expert commentary

07-06-2018 | Lung cancer | ASCO 2018 | Video

Expert highlights: Lung cancer research from ASCO 2018

Watch this video to find out which studies reported at the ASCO Annual Meeting 2018 caught the interest of Advisory board member Lecia Sequist. She also talks about her own research presented at the conference (6:38).

06-06-2018 | Gastrointestinal cancers | ASCO 2018 | Video

Expert commentary: GI highlights including the PRODIGE 7, PRODIGE 24, and PREOPANC trials

ASCO expert Andrew Epstein gives his account of some of the key trial findings in  gastointestinal cancer from this year's meeting (9:05).

06-06-2018 | Esophageal cancer | ASCO 2018 | Video

Researcher comment: Shedding light on the use of PPIs and aspirin in patients with Barrett’s esophagus

Janusz Jankowski discusses his team's findings from the AspECT study on the chemoprevention efficacy and safety of aspirin and esomeprazole in esophageal cancer (7:42). 

03-06-2018 | Prostate cancer | ASCO 2018 | Video

Expert commentary: Unpicking the relationship between prostate cancer treatment efficacy, survival and race

ASCO Expert Robert Dreicer reviews two studies looking at differences in survival rates between Black and White men with metastatic castration-resistant prostate cancer (3:16). 

Read the accompanying news story here.

03-06-2018 | Head and neck cancers | ASCO 2018 | Video

Expert commentary: Are women with head and neck cancer undertreated?

ASCO expert Joshua Jones comments on the outcomes of an analysis of cancer registry data from a California Hospital system that highlights a disparity in intensive treatment between men and women with head and neck cancer (2:57).

Read the accompanying news story here.

image credits